Literature DB >> 22711471

The effect of blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome in a rat model of subarachnoid hemorrhage.

Matthew Boyko1, Israel Melamed, Benjamin Fredrick Gruenbaum, Shaun Evan Gruenbaum, Sharon Ohayon, Akiva Leibowitz, Evgeny Brotfain, Yoram Shapira, Alexander Zlotnik.   

Abstract

Blood glutamate scavengers have been shown to effectively reduce blood glutamate concentrations and improve neurological outcome after traumatic brain injury and stroke in rats. This study investigates the efficacy of blood glutamate scavengers oxaloacetate and pyruvate in the treatment of subarachnoid hemorrhage (SAH) in rats. Isotonic saline, 250 mg/kg oxaloacetate, or 125 mg/kg pyruvate was injected intravenously in 60 rats, 60 minutes after induction of SAH at a rate of 0.1 ml/100 g/min for 30 minutes. There were 20 additional rats that were used as a sham-operated group. Blood samples were collected at baseline and 90 minutes after SAH. Neurological performance was assessed at 24 h after SAH. In half of the rats, glutamate concentrations in the cerebrospinal fluid were measured 24 h after SAH. For the remaining half, the blood brain barrier permeability in the frontal and parieto-occipital lobes was measured 48 h after SAH. Blood glutamate levels were reduced in rats treated with oxaloacetate or pyruvate at 90 minutes after SAH (p < 0.001). Cerebrospinal fluid glutamate was reduced in rats treated with pyruvate (p < 0.05). Neurological performance was significantly improved in rats treated with oxaloacetate (p < 0.05) or pyruvate (p < 0.01). The breakdown of the blood brain barrier was reduced in the frontal lobe in rats treated with pyruvate (p < 0.05) and in the parieto-occipital lobes in rats treated with either pyruvate (p < 0.01) or oxaloacetate (p < 0.01). This study demonstrates the effectiveness of blood glutamate scavengers oxaloacetate and pyruvate as a therapeutic neuroprotective strategy in a rat model of SAH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22711471      PMCID: PMC3441925          DOI: 10.1007/s13311-012-0129-6

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  73 in total

1.  Metabolic compartments in vivo. Ammonia and glutamic acid metabolism in brain and liver.

Authors:  S BERL; G TAKAGAKI; D D CLARKE; H WAELSCH
Journal:  J Biol Chem       Date:  1962-08       Impact factor: 5.157

Review 2.  Mechanisms of acute brain injury after subarachnoid hemorrhage.

Authors:  Fatima A Sehba; Joshua B Bederson
Journal:  Neurol Res       Date:  2006-06       Impact factor: 2.448

Review 3.  Subarachnoid haemorrhage.

Authors:  Jan van Gijn; Richard S Kerr; Gabriel J E Rinkel
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

4.  From the liver to the brain across the blood-brain barrier.

Authors:  Vivian I Teichberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

5.  Brain neuroprotection by scavenging blood glutamate.

Authors:  Alexander Zlotnik; Boris Gurevich; Sergei Tkachov; Ilana Maoz; Yoram Shapira; Vivian I Teichberg
Journal:  Exp Neurol       Date:  2006-10-02       Impact factor: 5.330

Review 6.  Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies.

Authors:  Valery L Feigin; Gabriel J E Rinkel; Carlene M M Lawes; Ale Algra; Derrick A Bennett; Jan van Gijn; Craig S Anderson
Journal:  Stroke       Date:  2005-11-10       Impact factor: 7.914

7.  NMDA receptor antagonist felbamate reduces behavioral deficits and blood-brain barrier permeability changes after experimental subarachnoid hemorrhage in the rat.

Authors:  Antonino Germanò; Mariella Caffo; Filippo Flavio Angileri; Francesca Arcadi; Jennifer Newcomb-Fernandez; Gerardo Caruso; Francesco Meli; Jose A Pineda; Stephen B Lewis; Kevin K W Wang; Placido Bramanti; Chiara Costa; Ronald L Hayes
Journal:  J Neurotrauma       Date:  2007-04       Impact factor: 5.269

Review 8.  Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists.

Authors:  Keith W Muir
Journal:  Curr Opin Pharmacol       Date:  2005-12-15       Impact factor: 5.547

9.  Neurological deterioration as a potential alternative endpoint in human clinical trials of experimental pharmacological agents for treatment of severe traumatic brain injuries. Executive Committee of the International Selfotel Trial.

Authors:  G F Morris; N Juul; S B Marshall; B Benedict; L F Marshall
Journal:  Neurosurgery       Date:  1998-12       Impact factor: 4.654

10.  Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis.

Authors:  Elisabeth Andreadou; Elisabeth Kapaki; Panagiotis Kokotis; George P Paraskevas; Nikolaos Katsaros; Georgia Libitaki; Olga Petropoulou; Vassilios Zis; Constantinos Sfagos; Demetrios Vassilopoulos
Journal:  In Vivo       Date:  2008 Jan-Feb       Impact factor: 2.155

View more
  23 in total

1.  Peripheral Interventions Enhancing Brain Glutamate Homeostasis Relieve Amyloid β- and TNFα- Mediated Synaptic Plasticity Disruption in the Rat Hippocampus.

Authors:  Dainan Zhang; Alexandra J Mably; Dominic M Walsh; Michael J Rowan
Journal:  Cereb Cortex       Date:  2017-07-01       Impact factor: 5.357

2.  Characterization of the L-glutamate clearance pathways across the blood-brain barrier and the effect of astrocytes in an in vitro blood-brain barrier model.

Authors:  Hans Cc Helms; Blanca I Aldana; Simon Groth; Morten M Jensen; Helle S Waagepetersen; Carsten U Nielsen; Birger Brodin
Journal:  J Cereb Blood Flow Metab       Date:  2017-02-01       Impact factor: 6.200

Review 3.  Taming glutamate excitotoxicity: strategic pathway modulation for neuroprotection.

Authors:  Ming Jia; Steve A Noutong Njapo; Vaibhav Rastogi; Vishnumurthy Shushrutha Hedna
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

4.  The effect of pyruvate on the development and progression of post-stroke depression: A new therapeutic approach.

Authors:  Dmitry Frank; Ruslan Kuts; Philip Tsenter; Benjamin F Gruenbaum; Yulia Grinshpun; Vladislav Zvenigorodsky; Ilan Shelef; Dmitry Natanel; Evgeny Brotfain; Alexander Zlotnik; Matthew Boyko
Journal:  Neuropharmacology       Date:  2019-05-31       Impact factor: 5.250

5.  Effect of Gastrodin on Early Brain Injury and Neurological Outcome After Subarachnoid Hemorrhage in Rats.

Authors:  Xinzhi Wang; Shuyue Li; Jinbang Ma; Chuangang Wang; Anzhong Chen; Zhenxue Xin; Jianjun Zhang
Journal:  Neurosci Bull       Date:  2019-01-23       Impact factor: 5.203

6.  Blood Glutamate Reducing Effect of Hemofiltration in Critically Ill Patients.

Authors:  Evgeni Brotfain; Ruslan Kutz; Julia Grinshpun; Benjamin F Gruenbaum; Shaun E Gruenbaum; Amit Frenkel; Agzam Zhumadilov; Vladimir Zeldetz; Yoav Bichovsky; Matthew Boyko; Moti Klein; Alexander Zlotnik
Journal:  Neurotox Res       Date:  2017-08-23       Impact factor: 3.911

Review 7.  Extracorporeal methods of blood glutamate scavenging: a novel therapeutic modality.

Authors:  Agzam Zhumadilov; Matthew Boyko; Shaun E Gruenbaum; Evgeny Brotfain; Federico Bilotta; Alexander Zlotnik
Journal:  Expert Rev Neurother       Date:  2015-04-12       Impact factor: 4.618

8.  Controversies and evolving new mechanisms in subarachnoid hemorrhage.

Authors:  Sheng Chen; Hua Feng; Prativa Sherchan; Damon Klebe; Gang Zhao; Xiaochuan Sun; Jianmin Zhang; Jiping Tang; John H Zhang
Journal:  Prog Neurobiol       Date:  2013-09-25       Impact factor: 11.685

9.  Blood glutamate grabbing does not reduce the hematoma in an intracerebral hemorrhage model but it is a safe excitotoxic treatment modality.

Authors:  Andrés da Silva-Candal; Alba Vieites-Prado; María Gutiérrez-Fernández; Ramón I Rey; Bárbara Argibay; David Mirelman; Tomás Sobrino; Berta Rodríguez-Frutos; José Castillo; Francisco Campos
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-04       Impact factor: 6.200

Review 10.  Lactate shuttling and lactate use as fuel after traumatic brain injury: metabolic considerations.

Authors:  Gerald A Dienel
Journal:  J Cereb Blood Flow Metab       Date:  2014-09-10       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.